News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hengrui Medicine Granted Approval To Market Cancer Drug In U.S.


6/24/2014 2:54:17 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Jiangsu Hengrui Medicine was approved by the FDA for US marketing of oxalipatin, a generic treatment for colon and rectum cancer. Hengrui, whose major focus is chemotherapies, has annual revenues of $1 billion. The company said the latest US approval is part of its globalization initiative. Hengrui already markets oxaliplatin in China and Europe.

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES